BRD4: An emerging prospective therapeutic target in glioma

被引：39

作者：

Yang, Hua ^{[1
]}

Li Wei ^{[2
]}

Xun, Yang ^{[1
]}

Yang, Anping ^{[1
]}

You, Hua ^{[2
]}

机构：

[1] Foshan Univ, Sch Med, Dept Basic Med & Biomed Engn, Foshan 528000, Guangdong, Peoples R China

[2] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, 78 Heng Zhi Gang Rd, Guangzhou 510095, Guangdong, Peoples R China

来源：

MOLECULAR THERAPY-ONCOLYTICS | 2021年 / 21卷

基金：

中国国家自然科学基金;

关键词：

BROMODOMAIN INHIBITOR OTX015; ENHANCED EFFICACY; BET INHIBITOR; GLIOBLASTOMA; PROTEINS; NANOPARTICLES; COMBINATION; ACTIVATION;

D O I：

10.1016/j.omto.2021.03.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4 inhibitors have entered clinical trials and achieved exciting results in tumor treatment. Recent clinical studies have shown that BRD4 expression in glioma is significantly higher than in the adjacent normal brain tissue. BRD4 inhibitors effectively penetrate the blood-brain barrier and target glioma tumor tissues but have little effect on normal brain tissues. Thus, BRD4 is a target for the treatment of glioma. In this study, we discuss the progress in the use of BRD4 inhibitors for glioma treatment, their mechanism of action, and their broad potential clinical application.

引用

页码：1 / 14

页数：14

共 70 条

[1] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].

Amorim, Sandy ;

Stathis, Anastasios ;

Gleeson, Mary ;

Iyengar, Sunil ;

Magarotto, Valeria ;

Leleu, Xavier ;

Morschhauser, Franck ;

Karlin, Lionel ;

Broussais, Florence ;

Rezai, Keyvan ;

Herait, Patrice ;

Kahatt, Carmen ;

Lokiec, Francois ;

Salles, Gilles ;

Facon, Thierry ;

Palumbo, Antonio ;

Cunningham, David ;

Zucca, Emanuele ;

Thieblemont, Catherine .

LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204

[2] BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling [J].

Andrieu, Guillaume ;

Tran, Anna H. ;

Strissel, Katherine J. ;

Denis, Gerald V. .

CANCER RESEARCH, 2016, 76 (22) :6555-6567

[3] OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models [J].

Berenguer-Daize, Caroline ;

Astorgues-Xerri, Lucile ;

Odore, Elodie ;

Cayol, Mylene ;

Cvitkovic, Esteban ;

Noel, Kay ;

Bekradda, Mohamed ;

MacKenzie, Sarah ;

Rezai, Keyvan ;

Lokiec, Francois ;

Riveiro, Maria E. ;

Ouafik, L'Houcine .

INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (09) :2047-2055

[4] Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study [J].

Berthon, Celine ;

Raffoux, Emmanuel ;

Thomas, Xavier ;

Vey, Norbert ;

Gomez-Roca, Carlos ;

Yee, Karen ;

Taussig, David Christopher ;

Rezai, Keyvan ;

Roumier, Christophe ;

Herait, Patrice ;

Kahatt, Carmen ;

Quesnel, Bruno ;

Michallet, Mauricette ;

Recher, Christian ;

Lokiec, Francois ;

Preudhomme, Claude ;

Dombret, Herve .

LANCET HAEMATOLOGY, 2016, 3 (04) :E186-E195

[5] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs [J].

Boi, Michela ;

Gaudio, Eugenio ;

Bonetti, Paola ;

Kwee, Ivo ;

Bernasconi, Elena ;

Tarantelli, Chiara ;

Rinaldi, Andrea ;

Testoni, Monica ;

Cascione, Luciano ;

Ponzoni, Maurilio ;

Mensah, Afua Adjeiwaa ;

Stathis, Anastasios ;

Stussi, Georg ;

Riveiro, Maria Eugenia ;

Herait, Patrice ;

Inghirami, Giorgio ;

Cvitkovic, Esteban ;

Zucca, Emanuele ;

Bertoni, Francesco .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1628-1638

[6] Therapeutic targets for inflammation-mediated airway remodeling in chronic lung disease [J].

Brasier, Allan R. .

EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (11) :931-939

[7] Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs [J].

Chamberlain, Philip P. ;

Lopez-Girona, Antonia ;

Miller, Karen ;

Carmel, Gilles ;

Pagarigan, Barbra ;

Chie-Leon, Barbara ;

Rychak, Emily ;

Corral, Laura G. ;

Ren, Yan J. ;

Wang, Maria ;

Riley, Mariko ;

Delker, Silvia L. ;

Ito, Takumi ;

Ando, Hideki ;

Mori, Tomoyuki ;

Hirano, Yoshinori ;

Handa, Hiroshi ;

Hakoshima, Toshio ;

Daniel, Thomas O. ;

Cathers, Brian E. .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2014, 21 (09) :803-809

[8] Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy [J].

Chelladurai, Prakash ;

Boucherat, Olivier ;

Stenmark, Kurt ;

Kracht, Michael ;

Seeger, Werner ;

Bauer, Uta-Maria ;

Bonnet, Sebastien ;

Pullamsetti, Soni Savai .

BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (01) :54-71

[9] Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition [J].

Chen, Chong ;

Liu, Yu ;

Lu, Chao ;

Cross, Justin R. ;

Morris, John P. ;

Shroff, Aditya S. ;

Ward, Patrick S. ;

Bradner, James E. ;

Thompson, Craig ;

Lowe, Scott W. .

GENES & DEVELOPMENT, 2013, 27 (18) :1974-1985

[10] The Prognostic and Therapeutic Value of PD-L1 in Gliomaa [J].

Chen, Ruo Qiao ;

Liu, Feng ;

Qiu, Xin Yao ;

Chen, Xiao Qian .

FRONTIERS IN PHARMACOLOGY, 2019, 9

← 1 2 3 4 5 6 7 →